Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
Nat Commun ; 14(1): 8421, 2023 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-38110439

RESUMEN

High-harmonic generation in solids allows probing and controlling electron dynamics in crystals on few femtosecond timescales, paving the way to lightwave electronics. In the spatial domain, recent advances in the real-space interpretation of high-harmonic emission in solids allows imaging the field-free, static, potential of the valence electrons with picometer resolution. The combination of such extreme spatial and temporal resolutions to measure and control strong-field dynamics in solids at the atomic scale is poised to unlock a new frontier of lightwave electronics. Here, we report a strong intensity-dependent anisotropy in the high-harmonic generation from ReS2 that we attribute to angle-dependent interference of currents from the different atoms in the unit cell. Furthermore, we demonstrate how the laser parameters control the relative contribution of these atoms to the high-harmonic emission. Our findings provide an unprecedented atomic perspective on strong-field dynamics in crystals, revealing key factors to consider in the route towards developing efficient harmonic emitters.

2.
Adv Skin Wound Care ; 35(8): 447-453, 2022 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-35588193

RESUMEN

BACKGROUND: Although wound management is a major component of all domains of healthcare, conventional therapeutics have numerous limitations. The endocannabinoid system of the skin, one of the major endogenous systems, has recently been connected to wound healing. Cannabinoids and their interactions with the endogenous chemical signaling system may be a promising therapeutic option because they address some of the fundamental pathways for physiologic derangement that underpin chronic integumentary wounds. RECENT ADVANCES: The therapeutic applications of cannabinoids are increasing because of their legalization and resulting market expansion. Recently, their immunosuppressive and anti-inflammatory properties have been explored for the treatment of wounds that are not effectively managed by conventional medicines. CRITICAL ISSUES: Failure to manage wounds effectively is associated with reduced quality of life, disability, mortality, and increased healthcare expenditures. Therapeutic options that can manage wounds effectively and efficiently are needed. In this review, the authors summarize recent advances on the use of cannabinoids to treat skin disorders with an emphasis on wound management. FUTURE DIRECTIONS: Effective wound management requires medicines with good therapeutic outcomes and minimal adverse effects. Despite the promising results of cannabinoids in wound management, further controlled clinical studies are required to establish the definitive role of these compounds in the pathophysiology of wounds and their usefulness in the clinical setting.


Asunto(s)
Cannabinoides , Terapia de Presión Negativa para Heridas , Cannabinoides/farmacología , Cannabinoides/uso terapéutico , Humanos , Terapia de Presión Negativa para Heridas/métodos , Calidad de Vida , Piel , Cicatrización de Heridas
3.
J Chem Phys ; 140(20): 204301, 2014 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-24880274

RESUMEN

The excited state dynamics of isolated sulfur dioxide molecules have been investigated using the time-resolved photoelectron spectroscopy and time-resolved photoelectron-photoion coincidence techniques. Excited state wavepackets were prepared in the spectroscopically complex, electronically mixed (B̃)(1)B1/(Ã)(1)A2, Clements manifold following broadband excitation at a range of photon energies between 4.03 eV and 4.28 eV (308 nm and 290 nm, respectively). The resulting wavepacket dynamics were monitored using a multiphoton ionisation probe. The extensive literature associated with the Clements bands has been summarised and a detailed time domain description of the ultrafast relaxation pathways occurring from the optically bright (B̃)(1)B1 diabatic state is presented. Signatures of the oscillatory motion on the (B̃)(1)B1/(Ã)(1)A2 lower adiabatic surface responsible for the Clements band structure were observed. The recorded spectra also indicate that a component of the excited state wavepacket undergoes intersystem crossing from the Clements manifold to the underlying triplet states on a sub-picosecond time scale. Photoelectron signal growth time constants have been predominantly associated with intersystem crossing to the (c̃)(3)B2 state and were measured to vary between 750 and 150 fs over the implemented pump photon energy range. Additionally, pump beam intensity studies were performed. These experiments highlighted parallel relaxation processes that occurred at the one- and two-pump-photon levels of excitation on similar time scales, obscuring the Clements band dynamics when high pump beam intensities were implemented. Hence, the Clements band dynamics may be difficult to disentangle from higher order processes when ultrashort laser pulses and less-differential probe techniques are implemented.

4.
Pediatr Transplant ; 17(1): 80-5, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23240598

RESUMEN

Pediatric valganciclovir dosing recommendations have not been extensively validated for prevention or treatment for CMV infection. As such, we performed a pharmacokinetic study to compare different valganciclovir dosing regimens and the potential benefits of individualized dose adjustments in children following organ transplantation. Ganciclovir AUCs were calculated from four plasma drug levels in pediatric SOT recipients aged six months through three yr receiving valganciclovir suspension by mouth. Of the 28 ganciclovir AUC calculations performed, 11 (39%) were outside the therapeutic target range of 40-60 mcg h/L leading to a valganciclovir dose adjustment. Current manufacturer-recommended dosing based on BSA and CrCl was estimated to result in therapeutic AUCs in fewer patients than the simple weight-based formula used in our institution (4 vs. 13; p = 0.017). An AUC calculation using only the two- and five-h measurements was strongly correlated with the AUC using all four time measurements (R(2) = 0.846; p < 0.001). A simple weight-based dosing approach gives a higher probability for therapeutic AUCs compared to the manufacturer-recommended dosing in pediatric transplant patients aged six months through three yr with normal renal function. An AUC calculated using two sample times might allow for fewer blood draws in the future.


Asunto(s)
Área Bajo la Curva , Ganciclovir/análogos & derivados , Trasplante de Órganos/métodos , Administración Oral , Algoritmos , Antivirales/administración & dosificación , Antivirales/farmacocinética , Peso Corporal , Preescolar , Infecciones por Citomegalovirus/prevención & control , Esquema de Medicación , Ganciclovir/administración & dosificación , Ganciclovir/farmacocinética , Humanos , Lactante , Reproducibilidad de los Resultados , Resultado del Tratamiento , Valganciclovir
5.
Opt Express ; 19(7): 6858-64, 2011 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-21451713

RESUMEN

By using the novel approach for pulse compression that combines spectral broadening in hollow-core fiber (HCF) with linear propagation in fused silica (FS), we generate 1.6 cycle 0.24 mJ laser pulses at 1.8 µm wavelength with a repetition rate of 1 kHz. These pulses are obtained with a white light seeded optical parametric amplifier (OPA) and shown to be passively carrier envelope phase (CEP) stable.


Asunto(s)
Amplificadores Electrónicos , Tecnología de Fibra Óptica/instrumentación , Rayos Láser , Diseño de Equipo , Análisis de Falla de Equipo
6.
Nature ; 460(7258): 972-7, 2009 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-19626004

RESUMEN

High harmonic emission occurs when an electron, liberated from a molecule by an incident intense laser field, gains energy from the field and recombines with the parent molecular ion. The emission provides a snapshot of the structure and dynamics of the recombining system, encoded in the amplitudes, phases and polarization of the harmonic light. Here we show with CO(2) molecules that high harmonic interferometry can retrieve this structural and dynamic information: by measuring the phases and amplitudes of the harmonic emission, we reveal 'fingerprints' of multiple molecular orbitals participating in the process and decode the underlying attosecond multi-electron dynamics, including the dynamics of electron rearrangement upon ionization. These findings establish high harmonic interferometry as an effective approach to resolving multi-electron dynamics with sub-Angström spatial resolution arising from the de Broglie wavelength of the recombining electron, and attosecond temporal resolution arising from the timescale of the recombination event.

7.
Opt Lett ; 34(12): 1894-6, 2009 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-19529739

RESUMEN

We report generation of 400 microJ, 13.1 fs, 1425 nm optical parametric amplifier laser pulses. Spectral broadening of a 100 Hz optical parametric amplifier laser source is achieved by self-phase modulation in an argon-filled hollow-core fiber, and dispersion compensation is performed using chirped mirrors. This laser source will be useful for ultrafast time-resolved molecular orbital tomography.

8.
Phys Rev Lett ; 102(6): 063601, 2009 Feb 13.
Artículo en Inglés | MEDLINE | ID: mdl-19257587

RESUMEN

We describe the roles of multiple electronic continua in high-harmonic generation from aligned molecules. First, we show how the circularity of emitted harmonics tracks the interplay of different electronic continua participating in the nonlinear response. Second, we show that the interplay of different continua can lead to large variations of harmonic phases. Finally, we show how multiple electronic continua allow one to shape the polarization of high harmonics and attosecond pulses.

9.
BMC Cancer ; 8: 318, 2008 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-18980695

RESUMEN

BACKGROUND: Anthracyclines and taxanes are commonly used in the treatment of breast cancer. However, tumor resistance to these drugs often develops, possibly due to overexpression of drug transporters. It remains unclear whether drug resistance in vitro occurs at clinically relevant doses of chemotherapy drugs and whether both the onset and magnitude of drug resistance can be temporally and causally correlated with the enhanced expression and activity of specific drug transporters. To address these issues, MCF-7 cells were selected for survival in increasing concentrations of doxorubicin (MCF-7DOX-2), epirubicin (MCF-7EPI), paclitaxel (MCF-7TAX-2), or docetaxel (MCF-7TXT). During selection cells were assessed for drug sensitivity, drug uptake, and the expression of various drug transporters. RESULTS: In all cases, resistance was only achieved when selection reached a specific threshold dose, which was well within the clinical range. A reduction in drug uptake was temporally correlated with the acquisition of drug resistance for all cell lines, but further increases in drug resistance at doses above threshold were unrelated to changes in cellular drug uptake. Elevated expression of one or more drug transporters was seen at or above the threshold dose, but the identity, number, and temporal pattern of drug transporter induction varied with the drug used as selection agent. The pan drug transporter inhibitor cyclosporin A was able to partially or completely restore drug accumulation in the drug-resistant cell lines, but had only partial to no effect on drug sensitivity. The inability of cyclosporin A to restore drug sensitivity suggests the presence of additional mechanisms of drug resistance. CONCLUSION: This study indicates that drug resistance is achieved in breast tumour cells only upon exposure to concentrations of drug at or above a specific selection dose. While changes in drug accumulation and the expression of drug transporters does occur at the threshold dose, the magnitude of resistance cannot be attributed solely to changes in drug accumulation or the activity of drug transporters. The identities of these additional drug-transporter-independent mechanisms are discussed, including their likely clinical relevance.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Antineoplásicos/farmacología , Resistencia a Antineoplásicos , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Análisis de Varianza , Antineoplásicos/metabolismo , Línea Celular Tumoral , Ciclosporina/farmacología , Docetaxel , Doxorrubicina/metabolismo , Doxorrubicina/farmacología , Epirrubicina/metabolismo , Epirrubicina/farmacología , Humanos , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Proteínas de Neoplasias/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Paclitaxel/metabolismo , Paclitaxel/farmacología , Estadísticas no Paramétricas , Taxoides/metabolismo , Taxoides/farmacología , Partículas Ribonucleoproteicas en Bóveda/metabolismo
10.
Epigenetics ; 3(5): 270-80, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19001875

RESUMEN

Drug transporters have been implicated in resistance of solid and non-solid tumors to a variety of chemotherapeutic agents. Higher expression of the ABCB1 drug transporter is often observed in drug-resistant tumor cells, although the precise mechanism remains unclear. During selection of MCF-7 cells for survival in increasing concentrations of docetaxel (MCF-7TXT cells), we observed in this study a temporal correlation between the acquisition of docetaxel resistance at selection dose 9 and the increased expression of ABCB1. Both the magnitude of docetaxel resistance and the level of ABCB1 expression then rose as the selection dose was further elevated. We also observed through bisulfite sequencing experiments that the ABCB1 downstream promoter became increasingly methylated following the acquisition of drug resistance (selection doses 10-12). Transcription was solely attributed to the upstream ABCB1 promoter within MCF-7TXT cells at the highest selection dose suggesting that hypermethylation caused a shift in promoter usage. The hypermethylation was also accompanied by regional amplification of chromosome 7 containing the ABCB1 gene and its neighbor ABCB4 but not DBF-4. The amplification of the ABCB1 gene correlated positively both with the hypermethylation of the ABCB1 downstream promoter (r=0.90) and the increased expression of ABCB1 (r=0.78). Moreover demethylation of the ABCB1 downstream promoter induced by 5-aza-2A'deoxycytidine treatment decreased the expression of ABCB1 mRNA in MCF-7TXT cells. Taken together, our findings suggest that the increased expression of ABCB1 upon acquisition of docetaxel resistance in breast tumor cells can be multifactorial, involving both epigenetic changes in promoter usage and regional chromosome amplification.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Neoplasias de la Mama/genética , Metilación de ADN , Resistencia a Antineoplásicos/genética , Amplificación de Genes , Regulación Neoplásica de la Expresión Génica , Subfamilia B de Transportador de Casetes de Unión a ATP , Antineoplásicos/farmacología , Línea Celular Tumoral , Docetaxel , Epigénesis Genética , Femenino , Expresión Génica , Humanos , Regiones Promotoras Genéticas , Taxoides/farmacología , Transcripción Genética
11.
Nature ; 449(7165): 997-9, 2007 Oct 25.
Artículo en Inglés | MEDLINE | ID: mdl-17960231
12.
Cell Biol Int ; 31(10): 1160-72, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17512223

RESUMEN

Expression of bovine PKCalpha in Saccharomyces cerevisiae results in growth inhibition, which is strongly augmented upon addition of phorbol esters. To investigate the nature of this PKC-induced inhibition of cell growth, wildtype and bovine PKCalpha-expressing yeast cells were examined by flow cytometry and by fluorescence microscopy after staining with propidium iodide. Upon expression and activation of the mammalian PKC isoform, cells accumulated in the G2/M phase of the cell cycle and exhibited impaired chromsome segregation. In some instances, PKC expression and activation was accompanied by a defect in septum formation between mother and daughter cells. cDNA microarray analysis revealed 4 genes (CTS1, DSE1, DSE2, and SVS1) that changed expression in both a PKCalpha- and phorbol ester-dependent manner. These findings were confirmed by quantitative real-time PCR. Three of these genes are involved in cell wall turnover and are regulated by a single transcription factor (Ace 2) that localizes to daughter cell nuclei after cytokinesis. Taken together, these observations suggest that expression and activation of bovine PKCalpha in yeast cells repress growth by inducing an accumulation of cells in G2/M, likely through an impairment of chromosome segregation, cytokinesis, and septum formation. Moreover, when these observations are taken in the context of previously published observations with various yeast null mutants, we propose that bovine PKCalpha may directly or indirectly activate a subunit of the PP2A phosphatase complex (cdc55), which is a component of the mitotic spindle checkpoint.


Asunto(s)
Pared Celular/metabolismo , Segregación Cromosómica , Regulación Fúngica de la Expresión Génica/fisiología , Proteína Quinasa C-alfa/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Saccharomyces cerevisiae/enzimología , Animales , Bovinos , División Celular , Proliferación Celular , Fase G2 , Perfilación de la Expresión Génica , Immunoblotting , Mitosis , Análisis de Secuencia por Matrices de Oligonucleótidos , Fosfoproteínas Fosfatasas/metabolismo , Reacción en Cadena de la Polimerasa , ARN de Hongos , Proteínas de Saccharomyces cerevisiae/genética , Huso Acromático
13.
Anticancer Drugs ; 18(5): 499-523, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17414620

RESUMEN

Genome profiling approaches such as cDNA microarray analysis and quantitative reverse transcription polymerase chain reaction are playing ever-increasing roles in the classification of human cancers and in the discovery of biomarkers for the prediction of prognosis in cancer patients. Increasing research efforts are also being directed at identifying set of genes whose expression can be correlated with response to specific drugs or drug combinations. Such genes hold the prospect of tailoring chemotherapy regimens to the individual patient, based on tumour or host gene expression profiles. This review outlines recent advances and challenges in using genome profiling for the identification of tumour or host genes whose expression correlates with response to chemotherapy drugs both in vitro and in clinical studies. Genetic predictors of response to a variety of anticancer agents are discussed, including the anthracyclines, taxanes, topoisomerase I and II inhibitors, nucleoside analogs, alkylating agents, and vinca alkaloids.


Asunto(s)
Antineoplásicos/farmacología , Biomarcadores/análisis , Perfilación de la Expresión Génica , Animales , Antraciclinas/farmacología , Antineoplásicos Alquilantes/farmacología , Antineoplásicos Fitogénicos/farmacología , Camptotecina/análogos & derivados , Camptotecina/farmacología , Línea Celular Tumoral , Humanos , Nucleósidos/farmacología , Valor Predictivo de las Pruebas , Taxoides/farmacología , Inhibidores de Topoisomerasa I , Inhibidores de Topoisomerasa II , Alcaloides de la Vinca/farmacología
14.
Breast Cancer Res Treat ; 96(1): 17-39, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16322897

RESUMEN

cDNA microarray analysis is a highly useful tool for the classification of tumors and for prediction of patient prognosis to specific cancers based on this classification. However, to date, there is little evidence that microarray approaches can be used to reliably predict patient response to specific chemotherapy drugs or regimens. This is likely due to an inability to differentiate between genes affecting patient prognosis and genes that play a role in response to specific drugs. Thus, it would be highly useful to identify genes whose expression correlates with tumor cell sensitivity to specific chemotherapy agents in a drug-specific manner. Using cDNA microarray analysis of wildtype MCF-7 breast tumor cells and isogenic paclitaxel-resistant (MCF-7(TAX)) or doxorubicin-resistant (MCF-7(DOX)) derivative cell lines, we have uncovered drug-specific changes in gene expression that accompany the establishment of paclitaxel or doxorubicin resistance. These changes in gene expression were confirmed by quantitative reverse transcription polymerase chain reaction and immunoblotting experiments, with a confirmation rate of approximately 91-95%. The genes identified may prove highly useful for prediction of response to paclitaxel or doxorubicin in patients with breast cancer. To our knowledge this is the first report of drug-specific genetic signatures of resistance to paclitaxel or doxorubicin, based on a comparison of gene expression between isogenic wildtype and drug-resistant tumor cell lines. Moreover, this study provides significant insight into the wide variety of mechanisms through which resistance to these agents may be acquired in breast cancer.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Antineoplásicos Fitogénicos/farmacología , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Doxorrubicina/farmacología , Resistencia a Antineoplásicos/genética , Análisis de Secuencia por Matrices de Oligonucleótidos , Paclitaxel/farmacología , Biomarcadores de Tumor/genética , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Femenino , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Células Tumorales Cultivadas
15.
Anal Biochem ; 345(2): 237-49, 2005 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-16139235

RESUMEN

cDNA microarray analysis is highly useful for monitoring genome-wide changes in gene expression that occur in biological processes. Current standards require that microarray observations be verified by quantitative (Q)-PCR or other techniques. Few studies have optimized Q-PCR for verification of microarray findings. The current study assessed several variables affecting Q-PCR fidelity, including RNA extraction methods, mRNA enrichment, primers for reverse transcription, and cDNA amplification detection methods. Also assessed was the choice of reference gene on which other gene expression changes are based. The RNA for ribosomal protein S28 was found to be ideal for this purpose, with minimal variance in expression among isogenic drug-resistant cell lines. We also found that oligo (dT) primers were superior to random hexamers and that RNA extracted by the RNeasy method gave consistent S28 gene amplification without the need for mRNA enrichment, particularly when TaqMan probes were used. Nevertheless, sensitivity was sufficiently high with SYBR Green I that it was the preferred, least costly method for amplification product detection, even for low-abundance transcripts. Using the optimal method, 91-95% of the differences in gene expression identified between the cell lines by cDNA microarray analysis could be confirmed by Q-PCR, significantly superior to previously described methods.


Asunto(s)
Análisis por Micromatrices , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Antibióticos Antineoplásicos/farmacología , Antineoplásicos Fitogénicos/farmacología , Benzotiazoles , Neoplasias de la Mama/patología , Línea Celular Tumoral , ADN Complementario/genética , Diaminas , Doxorrubicina/farmacología , Resistencia a Múltiples Medicamentos/genética , Femenino , Amplificación de Genes , Expresión Génica , Humanos , Compuestos Orgánicos , Paclitaxel/farmacología , Quinolinas , ARN/análisis , ARN Mensajero/metabolismo
16.
Science ; 307(5716): 1730-1, 2005 Mar 18.
Artículo en Inglés | MEDLINE | ID: mdl-15774747
17.
Curr Top Med Chem ; 4(13): 1327-1343, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15379648

RESUMEN

With the advent of DNA microarray analysis, it is now possible to examine the response of virtually the entire human genome to cellular drug exposure and to uncover a wide variety of genes correlating with the establishment of drug resistance. This relatively new field of "pharmacogenomics" is likely to vastly increase our understanding of the mechanisms of drug action and how cells respond and adapt to drug exposure. However, DNA microarray studies typically result in the identification of hundreds of genes that may or may not be of relevance in vivo-particularly when large, genetically diverse study populations are used. The challenge to the researcher is to design experimental systems and approaches which minimize variability in the data, increase the reproducibility amongst experiments, allow array data from multiple experiments to be assessed by a variety of statistical, supervised learning, and data clustering approaches, and provide a clear link between drug response and the expression of specific genes. This review provides a description and critical analysis of recent studies on the pharmacogenomics of drug response and discusses current guidelines and approaches for the performance and analysis of DNA microarray experiments in this area.


Asunto(s)
ADN/genética , Análisis de Secuencia por Matrices de Oligonucleótidos/métodos , Análisis de Secuencia por Matrices de Oligonucleótidos/estadística & datos numéricos , Farmacogenética/métodos , Farmacogenética/tendencias , Animales , Interpretación Estadística de Datos , Diseño de Fármacos , Resistencia a Antineoplásicos/genética , Perfilación de la Expresión Génica/métodos , Genoma Humano , Humanos
18.
Breast Cancer Res Treat ; 85(1): 31-51, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15039596

RESUMEN

Less than half of breast cancer patients respond to second-line chemotherapy with paclitaxel after failing treatment with anthracyclines such as doxorubicin. A recent clinical trial by Paridaens et al. [J. Clin. Oncol. 18 : 724-733, 2000] examined whether patients may derive a better clinical benefit if paclitaxel was administered before doxorubicin. While overall survival was similar regardless of the order of drug administration, a >4-fold reduction in the response rate to paclitaxel was observed after late crossover from doxorubicin, compared to the response rate to doxorubicin after late crossover from paclitaxel. This may be related to differences in the ability of the drugs to induce cross-resistance to each other. To test this hypothesis, we examined whether isogenic breast tumor cells selected for resistance to doxorubicin exhibit greater cross-resistance to paclitaxel and other drugs than identical cells selected for resistance to paclitaxel. We found that cells selected for resistance to paclitaxel showed strong resistance (>/=40-fold) to paclitaxel and docetaxel, with little cross-resistance (4-fold) to doxorubicin. In contrast, cells selected for resistance to doxorubicin exhibited 50-fold resistance to doxorubicin and a dramatic 4700-fold and 14,600-fold cross-resistance to paclitaxel and docetaxel, respectively. Doxorubicin-resistant cells exhibited higher P-glycoprotein and breast cancer resistance protein (BCRP) levels than paclitaxel-resistant cells. In addition, procaspase-9 was strongly downregulated in doxorubicin-resistant cells but not in paclitaxel-resistant cells. These differences may account for the contrasting cross-resistance profiles observed for the two cell lines and may help to explain why treatment of breast cancer patients with paclitaxel appears to be compromized by prior doxorubicin exposure.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Doxorrubicina/farmacología , Resistencia a Antineoplásicos/fisiología , Paclitaxel/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/efectos de los fármacos , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/efectos de los fármacos , Adenocarcinoma/fisiopatología , Neoplasias de la Mama/fisiopatología , Caspasa 9 , Caspasas/efectos de los fármacos , Línea Celular Tumoral , Interacciones Farmacológicas/fisiología , Humanos , Proteínas de Neoplasias/efectos de los fármacos
19.
Breast Cancer Res Treat ; 82(2): 125-41, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14692656

RESUMEN

Drug resistance is a major impediment to the successful treatment of breast cancer using chemotherapy. The photoactivatable drug calphostin C has shown promise in killing select drug-resistant tumor cells lines in vitro. To assess the effectiveness of this agent in killing doxorubicin- or paclitaxel-resistant breast tumor cells and to explore its mode of action, MCF-7 cells were exposed to increasing concentrations of either doxorubicin or paclitaxel until maximum resistance was obtained. This resulted in the creation of isogenic drug-resistant MCF-7TAX and MCF-7DOX cell lines, which were approximately 50- and 65-fold resistant to paclitaxel and doxorubicin, respectively. Interestingly, calphostin C was able to kill MCF-7TAX cells as efficiently as wildtype MCF-7 cells (IC50s were 9.2 and 13.2 nM, respectively), while MCF-7DOX cells required a 5-fold higher concentration of calphostin C to achieve the same killing (IC50 = 64.2 nM). Consistent with their known mechanisms of action, paclitaxel killed tumor cells by inducing mitotic arrest and cell multinucleation, while doxorubicin induced plasma membrane blebbing and decreased nuclear staining with propidium iodide. In contrast, cytoplasmic vacuolization accompanied cell killing by calphostin C in these cell lines, without the induction of caspase-8 or PARP cleavage or the release of cytochrome c from mitochondria. Calphostin C had little effect on the uptake of either paclitaxel or doxorubicin by the cells. Taken together, the above data suggests that calphostin C is able to potently kill drug-resistant breast tumor cells through a mechanism that may involve the induction of cytoplasmic vacuolization, without activation of typical apoptotic pathways. Consequently, calphostin C may prove useful clinically to combat tumor growth in breast cancer patients whose tumors have become unresponsive to anthracyclines or taxanes, particularly in association with photodynamic therapy.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Doxorrubicina/farmacología , Naftalenos/farmacología , Paclitaxel/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Caspasa 8 , Caspasas/metabolismo , Línea Celular Tumoral/efectos de los fármacos , Línea Celular Tumoral/metabolismo , Supervivencia Celular/efectos de los fármacos , Citocromos c/metabolismo , Citoplasma/efectos de los fármacos , ADN de Neoplasias/efectos de los fármacos , ADN de Neoplasias/metabolismo , Resistencia a Antineoplásicos , Citometría de Flujo , Humanos , Immunoblotting , Concentración 50 Inhibidora , Microscopía Fluorescente , Poli(ADP-Ribosa) Polimerasas/metabolismo , Vacuolas/efectos de los fármacos
20.
J Interpers Violence ; 18(11): 1325-34, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19774768

RESUMEN

The Self-Appraisal Questionnaire (SAQ) is a 72-item, self-report measure designed to predict recidivism, supervision violations, and related behaviors among nonmentally disordered Canadian federal offenders. In the present article, the authors demonstrate that the SAQ maintains satisfactory predictive validity on cross-validation with a high-risk correctional psychiatric sample.


Asunto(s)
Enfermos Mentales/psicología , Medición de Riesgo/métodos , Delitos Sexuales/psicología , Encuestas y Cuestionarios/normas , Adulto , Canadá , Estudios Transversales , Psiquiatría Forense/métodos , Hospitales Psiquiátricos , Humanos , Masculino , Persona de Mediana Edad , Psicometría , Reproducibilidad de los Resultados , Prevención Secundaria , Autoevaluación (Psicología) , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...